OTC · Biotechnology

Frontage Holdings Corporation (FGHQF) Stock

$0.15 +11.11% OTC: FGHQF Healthcare

Frontage Holdings Corporation operates as a contract research organization, furnishing an extensive array of laboratory and associated services to pharmaceutical, biotechnology, and agrochemical firms, in addition to conducting bioequivalence studies. Its service portfolio includes laboratory testing, covering method development, validation, sample analysis, and central laboratory functions.

Valuation

MetricValue
Price$0.15
Market Cap$304.16M
P/E Ratio44.83
P/B Ratio0.87
P/S Ratio1.17
EPS (TTM)$0.00
52-Week High$0.15
52-Week Low$0.11
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE1.98%
ROA1.26%
ROCE3.67%
Gross Margin26.96%
Operating Margin6.26%
Net Margin2.65%
Debt/Equity0.37
Current Ratio1.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$184.0M$251.0M$260.0M$255.0M$257.0M
Operating Profit$25.0M$33.0M$20.0M$9.0M$15.0M
Net Profit$18.0M$26.0M$11.0M$1.0M$7.0M
EPS$0.01$0.01$0.01$0.00$0.00
Op Margin13.7%13.2%7.8%3.7%5.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$476.0M$550.0M$572.0M$554.0M$541.0M
Total Liabilities$153.0M$215.0M$227.0M$219.0M$191.0M
Cash$146.0M$88.0M$53.0M$44.0M$37.0M
Borrowings$58.0M$118.0M$145.0M$154.0M$128.0M

Latest News

Frontage Laboratories Is Pleased to Welcome Dr. Chandra Prakash, Ph.D., as Senior Advisor, Clinical Services PR Newswire · Jun 29, 2026 Asian Penny Stocks To Watch In May 2026 Simply Wall St. · May 21, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$46.0M$62.0M$40.0M$41.0M$44.0M
Investing Cash Flow$-158.0M$-196.0M$-109.0M$-67.0M$-26.0M
Financing Cash Flow$-8.0M$-19.0M$-10.0M$-32.0M$-17.0M
Net Cash Flow$-67.0M$-58.0M$-34.0M$-9.0M$-8.0M
Free Cash Flow$-4.0M$14.0M$19.0M$15.0M$32.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.04
EV / EBITDA9.33
FCF Yield10.76%
Quick Ratio1.31
Interest Coverage2.18
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held73.65%
Institutions Held0.17%
Institutions Float Held0.66%
Institutional HolderSharesReport Date
DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT.1,256,0002026-04-30
DFA INVESTMENT TRUST CO-The Asia Pacific Small Company Series826,0002026-04-30
Dimensional ETF Trust-Dimensional International Small Cap ETF162,0002026-04-30
LINCOLN Varbl INSURANCE Prod. TRT-LVIP Dimensional Intl Core Eqy. Fd.64,0002026-03-31
John Hancock Varbl Insurance TRT-Intl Small Company TRT14,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CLVLFClinuvel Pharmaceuticals Limited $6.37 +0.00% 13.94 $321.12M 0.47%
CLVLYClinuvel Pharmaceuticals Limited $6.83 -2.57% 13.94 $344.42M 0.44%
CMVLFCellectis S.A. $3.47 +12.66% -4.24 $251.93M 0.00%
CYDYCytoDyn Inc. $0.19 +0.00% -5.94 $260.25M 0.00%
HNSBFHansa Biopharma AB $2.90 +0.00% -4.72 $289.23M 0.00%

About Frontage Holdings Corporation

Frontage Holdings Corporation operates as a contract research organization, furnishing an extensive array of laboratory and associated services to pharmaceutical, biotechnology, and agrochemical firms, in addition to conducting bioequivalence studies. Its service portfolio includes laboratory testing, covering method development, validation, sample analysis, and central laboratory functions. The company also delivers chemistry, manufacturing, and control (CMC) services, which involve assisting with drug product development and analysis, alongside the provision and supply of materials for clinical trials. Furthermore, Frontage offers drug metabolism and pharmacokinetic (DMPK) services, encompassing study design, execution, and data interpretation, from early discovery structural optimization to pharmacokinetic assessments in rodents and non-GLP bioanalytical studies. Its expertise extends to safety and toxicology, performed through both in-vitro and in-vivo studies. The company also handles bioequivalence services, managing their design, coordination, and reporting, as well as general chemistry services like contract research and custom synthesis. Lastly, clinical services are provided, including early-stage trials, bioequivalence/bioavailability (BE/BA) studies, biometrics, and data management. Established in 2018 and headquartered in Exton, Pennsylvania, Frontage maintains a global presence, operating in the United States, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. It functions as a subsidiary of Hongkong Tigermed Co., Limited.

Frontage Holdings Corporation is headquartered in US.

Frontage Holdings Corporation (FGHQF) stock trades at $0.15 with a market capitalization of $304.16M. The stock is valued at a price-to-earnings (P/E) ratio of 44.83, price-to-book of 0.87, price-to-sales of 1.17. Over the past 52 weeks the stock has ranged between $0.11 and $0.15, and currently trades at its 52-week high.

On profitability, Frontage Holdings Corporation generates a return on equity (ROE) of 1.98%, return on capital employed of 3.67%, an operating margin of 6.26%, a net profit margin of 2.65%.

Official website: www.frontagelab.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides